Publication Name	World Journal of Nephrology
Manuscript ID	14710
Country	United States

Received	2014-10-21 08:44
Peer-Review Started	2014-10-21 16:52
To Make the First Decision	2014-11-27 11:47
Return for Revision	2014-11-28 13:24
Revised	2015-03-11 07:18
Second Decision	2015-03-24 17:07
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-04-07 16:34
Articles in Press	2015-04-07 16:34
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-06-30 14:19
Publish the Manuscript Online	2015-07-06 18:45

ISSN	2220-6124 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Transplantation
Manuscript Type	Minireviews
Article Title	Modern approaches to incompatible kidney transplantation
Manuscript Source	Invited Manuscript
All Author List	Patarapha Wongsaroj, Joseph Kahwaji, Ashley Vo and Stanley C Jordan
Funding Agency and Grant Number
Corresponding Author	Joseph Kahwaji, MD, MPH, Cedars-Sinai Medical Center, Comprehensive Transplant Center, 8900 Beverly Blvd, Los Angeles, CA 90048, Unites States. kahwajij@cshs.org
Key Words	Desensitization; Antibodies; Intravenous immunoglobulin; Rituximab; ABO incompatible; Eculizumab; Bortezomib
Core Tip	Intravenous immunoglobulin (IVIG) remains the backbone of human-leukocyte antigen (HLA) desensitization therapy and excellent outcomes with the addition of rituximab (anti-B cell) have been achieved. Bortezomib (anti-plasma cell) and eculizumab (complement inhibition) may be good adjuncts for patients who are broadly sensitized with strong, complement-fixing HLA antibodies. Excellent outcomes have been achieved in ABO incompatible transplantation with the combination of antibody removal, B cell depletion, and pre-transplant immunosuppression. Kidney paired donation has emerged as a reasonable alternative for programs who cannot provide desensitization or in conjunction with desensitization.
Publish Date	2015-07-06 18:45
Citation	Wongsaroj P, Kahwaji J, Vo A, Jordan SC. Modern approaches to incompatible kidney transplantation. World J Nephrol 2015; 4(3): 354-362
URL	http://www.wjgnet.com/2220-6124/full/v4/i3/354.htm
DOI	http://dx.doi.org/10.5527/wjn.v4.i3.354

Full Article (PDF)	WJN-4-354.pdf
Full Article (Word)	WJN-4-354.doc
Manuscript File	14710-Review.docx
Answering Reviewers	14710-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	14710-Conflict-of-interest statement.pdf
Copyright License Agreement	14710-Copyright assignment.pdf
Peer-review Report	14710-Peer-review(s).pdf
Scientific Misconduct Check	14710-Scientific misconduct check.pdf
Scientific Editor Work List	14710-Scientific editor work list.pdf